Patient guide
Fact-checked by Dr. Adam Kennah, MD on . See our fact-checking policy.
A reference of clinically significant drug interactions involving GLP-1 receptor agonists. Not a substitute for clinical judgment — if you take any of the medications listed here, ensure your prescribing clinician is aware before starting a GLP-1.
GLP-1 RAs combined with insulin or sulfonylureas (glipizide, glyburide, glimepiride) substantially increase the risk of hypoglycemia. When initiating a GLP-1 RA in a patient already on insulin or a sulfonylurea, the dose of the concomitant agent typically must be reduced.
| Combination | Effect | Management |
|---|---|---|
| GLP-1 RA + insulin | ↑ hypoglycemia risk | Reduce insulin dose, monitor BG more frequently during titration |
| GLP-1 RA + sulfonylurea | ↑ hypoglycemia risk | Reduce sulfonylurea dose by 20-50% at initiation; consider discontinuation at higher GLP-1 doses |
| GLP-1 RA + metformin | No significant interaction | Generally well-tolerated combination; metformin can be continued |
| GLP-1 RA + DPP-4 inhibitor | Redundant mechanism | Not generally co-prescribed; discontinue DPP-4 inhibitor when starting GLP-1 RA |
| GLP-1 RA + SGLT-2 inhibitor | No significant interaction; complementary mechanisms | Frequently co-prescribed for additive HbA1c reduction |
GLP-1 RAs slow gastric emptying, which can delay the absorption of oral medications. Clinically relevant for narrow-therapeutic-index drugs.
| Affected medication | Consideration |
|---|---|
| Warfarin | Monitor INR more closely during GLP-1 RA initiation and dose titration. Delayed absorption may shift INR readings. |
| Levothyroxine | Take levothyroxine ≥30 minutes before food, as usual. No formal dose adjustment but TSH monitoring is reasonable. |
| Combined oral contraceptives | Theoretical concern for reduced efficacy during severe nausea/vomiting. Backup contraception recommended during titration if significant GI symptoms occur. |
| Oral antidiabetic agents | Absorption may be delayed but not clinically meaningful at standard doses. |
| Antibiotics (oral) | Tetracyclines and quinolones — standard administration; no specific GLP-1 interaction documented. |
GLP-1 RAs delay gastric emptying. The American Society of Anesthesiologists has issued guidance on perioperative GLP-1 management:
| Condition | Status | Reason |
|---|---|---|
| Personal/family history of medullary thyroid carcinoma | Contraindicated | Boxed warning |
| Multiple endocrine neoplasia syndrome type 2 | Contraindicated | Boxed warning |
| History of pancreatitis | Use with caution / avoid | Postmarketing reports of acute pancreatitis |
| Severe gastroparesis | Avoid | GLP-1 RAs further slow gastric emptying |
| Pregnancy | Avoid (Category C) | Animal data show fetal harm; insufficient human data |
| Active diabetic retinopathy | Use with caution | Rapid HbA1c reduction may transiently worsen retinopathy |
| Severe renal impairment (eGFR <15) | Use with caution | Limited data; volume-depletion risk from GI losses |
GLP-1 RAs do not have a direct pharmacological interaction with alcohol. Anecdotal reports suggest reduced alcohol cravings on GLP-1 therapy; this is under active clinical investigation for alcohol use disorder. There is no contraindication to moderate alcohol use, though heavy alcohol use complicates assessment of pancreatic injury risk.
If you are a prescribing clinician evaluating a patient for GLP-1 therapy, the most current authoritative interaction data is in the FDA-approved package insert for the specific GLP-1 product (Ozempic, Wegovy, Mounjaro, Zepbound, etc.). The labels are publicly available via DailyMed.